Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Applied BioCode said on Monday that is has submitted a new nucleic acid extraction claim for its BioCode Respiratory Pathogen Panel (RPP) to the US Food and Drug Administration, with the goal of expanding use of the panel by clinical laboratories.

Following decades of cumulative efforts, a number of infectious disease tests and technologies broke new ground in 2025, hinting at rapid advances in the development of new systems and assays. But the past year also saw its fair share of upheaval, possibly suggesting more may be in store in 2026.

Chinese molecular diagnostics and precision medicine firm GenePlus Technology said on Sunday that it has filed for an initial public offering on the Hong Kong Stock Exchange.

Singlera Genomics said on Tuesday that it has entered into a research and distribution agreement with EU-based international medical company Pure Medical for its cell-free DNA detection products.

Zydus Lifesciences said on Friday that it has signed an agreement to exclusively commercialize a trio of Myriad Genetics cancer tests in India.

Guardant Health Japan said Monday that it has received approval from that country's Ministry of Health, Labour, and Welfare (MHLW) for its Guardant360 CDx as a companion diagnostic for identifying ESR1 mutations in breast cancer patients.

Results of a Phase I clinical trial published on Tuesday demonstrate that Personalis' minimal residual disease (MRD) assay, NeXT Personal, accurately predicts immunotherapy response across multiple metastatic solid tumor cancer types.

Singlera Genomics and its partner Breakthrough Genomics this week announced a research collaboration with the University of Pittsburgh around the early detection of pancreatic cancer.

The Chinese University of Hong Kong (CUHK) said Wednesday that it has struck a deal with startup MicroSigX Biotech Diagnostic to offer an investigational microbiome test for autism to 200 eligible children under a pilot project.

Solvd Health said Wednesday that its pharmacogenomics (PGx) test PreScript has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP).